Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

BeOne Medicines is the lead sponsor of 40 current clinical trials in our USA, China, UK and Ireland registers. 30 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Sonrotoclax, Zanubrutinib and Tislelizumab. The most-studied condition is Advanced Solid Tumor.

ClinicalTrials.gov trials by status

Recruiting3075%
Active, closed1025%

Trials by phase

Phase 11743%
Phase 31230%
Phase 1/2718%
Phase 238%
Phase 2/313%

Clinical trials sponsored by BeOne Medicines

40 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Drugs: Pirtobrutinib, Tacabrutideg	Phase 3	Recruiting	2025-09	UK, USA, China
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Drugs: Obinutuzumab, Rituximab, Sonrotoclax	Phase 3	Recruiting	2025-06	Ireland, UK, USA, China
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia NCT07277231 · Chronic Lymphocytic Leukemia Drugs: Acalabrutinib, Sonrotoclax, Venetoclax	Phase 3	Recruiting	2026-01	UK, USA, China
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors NCT06846671 · CLL, Chronic Lymphocytic Leukemia Drugs: Bendamustine, Idelalisib, Rituximab	Phase 3	Recruiting	2025-04	UK, USA
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. NCT06697184 · Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma Drugs: Sonrotoclax, Zanubrutinib	Phase 1/2	Recruiting	2025-01	UK, USA
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease NCT07492641 · HR+/HER2- Breast Cancer Drugs: Abemaciclib, BGB-43395, Letrozole	Phase 3	Recruiting	2026-05	UK, USA, China
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) NCT06742996 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma, B Cell Lymphoma Drugs: Sonrotoclax, Zanubrutinib	Phase 3	Recruiting	2025-03	UK, USA, China
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors NCT07222267 · ClinicalTrials.gov ↗ · Breast Cancer, Advanced Solid Tumor Drug: BG-75202	Phase 1	Recruiting	2025-12	USA, China
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716 · ClinicalTrials.gov ↗ · B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma Drug: Tacabrutideg	Phase 1/2	Recruiting	2021-09	UK, USA, China
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors NCT06625593 · Advanced Solid Tumor	Phase 1	Recruiting	2024-12	USA, China
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma Drugs: Carfilzomib, Daratumumab, Dexamethasone	Phase 1/2	Recruiting	2021-09	UK, USA, China
A Study of BGB-11417 in Participants With Myeloid Malignancies NCT04771130 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm Drugs: Azacitidine, Posaconazole, Sonrotoclax	Phase 1/2	Recruiting	2021-05	UK, USA, China
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors NCT06233942 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Bevacizumab, Tislelizumab	Phase 1	Recruiting	2024-04	USA, China
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Drugs: Capecitabine, Cisplatin, Ivonescimab	Phase 3	Recruiting	2025-08	UK, USA, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants NCT07005713 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria Drug: Tacabrutideg	Phase 1	Recruiting	2025-07	China
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer NCT06756932 · ClinicalTrials.gov ↗ · Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Drugs: BGB-43395, Fulvestrant	Phase 1	Recruiting	2025-02	USA, China
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors NCT06589596 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2025-01	USA, China
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors NCT07181681 · ClinicalTrials.gov ↗ · Solid Tumors, Advanced Solid Tumor	Phase 1	Recruiting	2025-11	USA, China
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors NCT05981703 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Solid Tumor Drug: Tislelizumab	Phase 1	Recruiting	2023-09	USA, China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · ClinicalTrials.gov ↗ · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma Drugs: Capecitabine, Ivonescimab, Leucovorin	Phase 2	Recruiting	2026-04	USA
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies NCT06634589 · ClinicalTrials.gov ↗ · B-cell Malignancy, Relapsed Cancer, Refractory Cancer Drugs: Glofitamab, Mosunetuzumab, Obinutuzumab	Phase 1/2	Recruiting	2024-11	USA, China
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors NCT07226349 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: BGB-43395, Fulvestrant	Phase 1	Recruiting	2025-12	USA, China
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors NCT06803680 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1	Recruiting	2025-03	USA, China
A Study of BG-C477 in Participants With Advanced Solid Tumors NCT06596473 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Tislelizumab	Phase 1	Recruiting	2024-10	USA, China
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors NCT06598800 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2024-10	USA, China
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors NCT06427941 · ClinicalTrials.gov ↗ · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer Drugs: Bevacizumab, Tislelizumab	Phase 1/2	Recruiting	2024-07	USA, China
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors NCT06120283 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Drugs: BGB-43395, Elacestrant, Fulvestrant	Phase 1	Recruiting	2023-12	USA, China
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: Tislelizumab	Phase 1	Recruiting	2026-04	USA, China
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies NCT07619287 · ClinicalTrials.gov ↗ · Myeloid Malignancy Drug: BG-75202	Phase 1	Recruiting	2026-06	China
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases NCT07412691 · ClinicalTrials.gov ↗ · Skin Diseases	Phase 1	Recruiting	2026-03	China
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma NCT05100862 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma Drugs: Lenalidomide, Obinutuzumab, Rituximab	Phase 3	Active, closed	2022-03	Ireland, UK, USA, China
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation NCT04002297 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma; Non-Hodgkin Lymphoma Drugs: Bendamustine, Rituximab, Zanubrutinib	Phase 3	Active, closed	2019-08	Ireland, UK, USA, China
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy NCT05707377 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy Drugs: Tacrolimus, Zanubrutinib	Phase 2/3	Active, closed	2023-04	UK, USA, China
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma NCT05471843 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Drug: Sonrotoclax	Phase 1/2	Active, closed	2022-09	UK, USA, China
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) NCT06073821 · ClinicalTrials.gov ↗ · CLL Drugs: Obinutuzumab, Sonrotoclax, Venetoclax	Phase 3	Active, closed	2023-11	UK, USA, China
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies NCT04277637 · ClinicalTrials.gov ↗ · Mature B-Cell Malignancies Drugs: Obinutuzumab, Sonrotoclax, Zanubrutinib	Phase 1	Active, closed	2020-03	UK, USA
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib NCT04170283 · ClinicalTrials.gov ↗ · B-cell Malignancies Drugs: Tislelizumab, Zanubrutinib	Phase 3	Active, closed	2020-01	UK, USA, China
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia NCT05952037 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Drugs: Sonrotoclax, Zanubrutinib	Phase 2	Active, closed	2023-10	UK, USA, China
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia NCT06637501 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia Drugs: Sonrotoclax, Zanubrutinib	Phase 2	Active, closed	2024-11	USA, China
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors NCT06970743 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Drugs: Bendamustine, Chlorambucil, Methylprednisolone	Phase 3	Active, closed	2025-05	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in BeOne Medicines trials

37 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in BeOne Medicines trials

50 conditions

Advanced Solid Tumor11 Chronic Lymphocytic Leukemia7 Small Lymphocytic Lymphoma3CLL3Mantle Cell Lymphoma3 Marginal Zone Lymphoma2B-cell Malignancy2Hormone-receptor-positive Breast Cancer2 Metastatic Breast Cancer2Relapsed/Refractory Follicular Lymphoma1Mantle Cell Lymphoma; Non-Hodgkin Lymphoma1MCL1HR+/HER2- Breast Cancer1 B Cell Lymphoma1 Primary Membranous Nephropathy1Refractory Mantle Cell Lymphoma (MCL)1Relapsed Mantle Cell Lymphoma1Mature B-Cell Malignancies1Follicular Lymphoma1 Non-Hodgkin Lymphoma1 B-cell Malignancies1 Relapsed/Refractory Multiple Myeloma1 Acute Myeloid Leukemia1 Myelodysplastic Syndromes1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	36	27
Clinical trials in China	36	27
Clinical trials in UK	19	11
Clinical trials in Ireland	3	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumor

Sponsor	Trials
Daiichi Sankyo	7
TORL Biotherapeutics	5
OncoC4	5
LaNova Medicines	5
MediLink Therapeutics (Suzhou)	4
Suzhou Zelgen Biopharmaceuticals	4
BioNTech	3
EMD Serono Research & Development Institute	3
Hansoh BioMedical R&D Company	3
Qilu Pharmaceutical	3

Sponsors with the most current trials registered for this condition.

Questions about BeOne Medicines trials

How many clinical trials does BeOne Medicines sponsor?

BeOne Medicines is the lead sponsor of 40 current trials on ClinicalTrials.gov in our USA, China, UK and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are BeOne Medicines trials recruiting?

Yes. 30 of its 40 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is BeOne Medicines testing?

Its current trials name 37 drugs and biologicals as interventions. The most frequent are Sonrotoclax (12), Zanubrutinib (12), Tislelizumab (8), Obinutuzumab (6) and Tacabrutideg (6). The number in brackets is how many of its trials name each drug.

Does BeOne Medicines have clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

BeOne Medicines clinical trials